newsfilter
← Latest News
GlobeNewswire·

Crescent Biopharma Announces Grants of Inducement Awards

  • Crescent Biopharma's independent Compensation Committee approved equity inducement awards on May 28, 2026, pursuant to Nasdaq Listing Rule 5635(c)(4).
  • The awards consist of options to purchase an aggregate of 16,950 ordinary shares granted to two non-executive employees.
  • The options have a 10-year term with an exercise price of $21.47, based on the closing share price on May 28, 2026.
  • Vesting schedules include 25% of shares exercisable on the first anniversary of the start date, with monthly vesting of 1/48th of shares thereafter.
  • Vesting is contingent upon continuous service with Crescent Biopharma through the applicable dates under the 2025 Employment Inducement Incentive Award Plan.
  • Crescent Biopharma is a clinical-stage oncology company developing a PD-1 x VEGF bispecific antibody & antibody-drug conjugates for solid tumors.